Compositions and methods for treating cancer expressing CD90 and CD326

A method of treating a subject having a human cancer comprising cancerous cells that co-express CD90 and CD326, wherein the method comprises:

• a) administering to said subject a tagged first polypeptide having an antigen binding domain specific for CD90, and
• b) administering to said subject a tagged second polypeptide having an antigen binding domain specific for CD326, wherein the tag of the first polypeptide and the tag of the second polypeptide are identical, and
• c) administering to said subject an immune cell comprising a chimeric antigen receptor (CAR), the CAR comprising:
• i) an antigen binding domain specific for said tag of the first and second polypeptides,
• ii) a transmembrane domain, and
• iii) an intracellular signaling domain comprising a primary signaling domain and at least one costimulatory domain, thereby treating the subject having said human cancer.

An in vitro combination comprising an antigen binding domain specific for CD90 and an antigen binding domain specific for CD326, wherein the in vitro combination comprises:

• a) a tagged first polypeptide having the antigen binding domain specific for CD90;
• b) a tagged second polypeptide having the antigen binding domain specific for CD326, wherein the tag of the first polypeptide and the tag of the second polypeptide are identical;
• and
• c) an immune cell comprising a chimeric antigen receptor (CAR), the CAR comprising:
• i) an antigen binding domain specific for the tag of the first polypeptide and the tag of the second polypeptide;
• ii) a transmembrane domain, and
• iii) an intracellular signaling domain comprising a primary signaling domain and at least one costimulatory domain.